Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arecoline is a naturally occurring alkaloid and the primary psychoactive compound found in the areca nut, the fruit of the Areca catechu palm. It acts as a mild parasympathomimetic stimulant with both central and peripheral nervous system effects. Pharmacologically, arecoline is primarily a partial agonist at muscarinic acetylcholine receptors (notably M1, M2, and M3 subtypes), leading to increased parasympathetic activity. It also exhibits weak partial agonist or antagonist activity at certain nicotinic acetylcholine receptor subtypes (such as α4-, α6-, and α7-containing nAChRs). Arecoline has been used historically as a ganglionic stimulant, vermifuge (anti-parasitic agent), and for its euphoriant properties in traditional practices. In veterinary medicine, it has been employed to treat tapeworm infections. Experimental uses have included treatment of presenile dementia (including Alzheimer's disease) and schizophrenia symptoms due to its cholinergic activity[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Arecoline.